SAN DIEGO, October 8, 2015 /PRNewswire/ – ProSciento Inc., a clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today the launch of its white paper series focused on current developments in clinical research, biomarker development and disease management.
The company’s white papers, named ProSciento Focus Papers, narrow in on one area of expertise and are authored by key scientific thought leaders. The most recent Focus Papers of this series are titled:
- Current and Future Perspectives on the Development of Biosimilar Insulins for Diabetes Management
- Considerations for Evaluating the Cardiovascular Safety of Novel Treatments for Diabetes
- Recruitment Considerations for Early Phase Clinical Trials in Diabetes
The papers are available for download from ProSciento’s online Knowledge Library. Additional Focus Papers on topics related to diabetes, obesity and NAFLD/NASH will be added regularly.
About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
For business development inquires:
For clinical study enrollment inquires:
Tel: +1 (866) 308-7427